From Compliance to Competitive Advantage: How Regulatory Affairs Can Operationalize the EMA/FDA AI Principles

Posted on August 27, 2026 By Astrix Technology Group Blog, Featured Content

In January 2026, the FDA and EMA jointly published *Good AI Practice in Drug Development—10 principles*, establishing a framework for responsible AI use across the drug product life cycle, including nonclinical, clinical, post-marketing, and manufacturing activities.

This broad scope brings Regulatory Affairs directly into AI governance. Regulatory Affairs is uniquely positioned to lead, with visibility across the submission life cycle, expertise in GxP compliance and data integrity, and established relationships with health authorities.

Organizations that adopt these principles as an operating model—not simply a compliance requirement—can accelerate AI adoption while maintaining regulatory confidence.

**The industry challenge:** How can Regulatory Affairs accelerate submissions and content creation while strengthening documentation to meet evolving compliance standards?

by Astrix Technology Group